4,791 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by WCM Investment Management LLC

WCM Investment Management LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 4,791 shares of the biotechnology company’s stock, valued at approximately $465,000.

Several other institutional investors also recently bought and sold shares of the business. Aquila Investment Management LLC raised its holdings in BioMarin Pharmaceutical by 62.5% in the 4th quarter. Aquila Investment Management LLC now owns 13,000 shares of the biotechnology company’s stock valued at $1,253,000 after acquiring an additional 5,000 shares during the last quarter. Cerity Partners LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at $299,000. Moody Aldrich Partners LLC raised its holdings in BioMarin Pharmaceutical by 24.6% in the 4th quarter. Moody Aldrich Partners LLC now owns 7,049 shares of the biotechnology company’s stock valued at $680,000 after acquiring an additional 1,392 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in BioMarin Pharmaceutical by 7,368.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 60,571 shares of the biotechnology company’s stock valued at $5,840,000 after acquiring an additional 59,760 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter valued at $3,598,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $92.22 on Monday. The firm’s 50 day moving average is $87.46 and its two-hundred day moving average is $89.06. BioMarin Pharmaceutical Inc. has a 52 week low of $76.02 and a 52 week high of $100.38. The firm has a market capitalization of $17.40 billion, a P/E ratio of 104.80, a PEG ratio of 1.76 and a beta of 0.31. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. During the same quarter last year, the business earned $0.11 earnings per share. BioMarin Pharmaceutical’s revenue was up 20.2% compared to the same quarter last year. Analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BMRN shares. Stifel Nicolaus restated a “buy” rating and set a $101.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Canaccord Genuity Group restated a “hold” rating and set a $91.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Piper Sandler decreased their price target on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $107.61.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 2,286 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total value of $205,740.00. Following the completion of the transaction, the chief accounting officer now directly owns 16,156 shares in the company, valued at $1,454,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Jean Jacques Bienaime sold 15,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $88.28, for a total value of $1,324,200.00. Following the completion of the transaction, the director now directly owns 419,602 shares in the company, valued at $37,042,464.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Erin Burkhart sold 2,286 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total transaction of $205,740.00. Following the sale, the chief accounting officer now owns 16,156 shares of the company’s stock, valued at $1,454,040. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 83,229 shares of company stock worth $7,237,767. 1.84% of the stock is owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.